Scott Eggener, MD
While the United States Preventative Services Task Force (USPSTF) has taken a stand against routine prostate-specific antigen (PSA) screening for prostate cancer, updated findings from the landmark Prostate, Lung, Colorectal, and Ovary (PLCO) screening trial could flip opinions, explains Scott Eggener, MD.
during the meeting, Eggener, associate professor of Surgery, Urologic Oncology, at the University of Chicago Medicine, discusses the implications of the PLCO trial update, and shares his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer.
OncLive: What do oncologists need to know regarding the current landscape of early prostate cancer?
: Smart PSA-based screening can absolutely save lives. We have a problem with overdetection and overtreatment of men who are unlikely to benefit from it, so the gist of it is to identify men who have a reasonable life expectancy, are well informed, are interested in PSA screening, and can be biopsied appropriately.
In addition to that, there are many novel screening biomarkers—tissue-based biomarkers with good science and data behind them, and there are advances. The upcoming—and current—challenge is how to integrate them appropriately into the standard care pathways, particularly given their typically excessive cost.
Can you shed light on some of those biomarkers?
In the screening setting, there are a lot of very strong data showing [the efficacy of] the 4Kscore, the Prostate Health Index, and the MiPS score. There’s a SelectMDx score that recently presented some data. After the diagnosis—once someone has a biopsy showing cancer—there are tissue-based biomarkers such as Prolaris, Oncotype DX, and GenomeDX.
There were some interesting findings recently presented on the PLCO trial. It seems to go against what the USPSTF was pushing for this whole time. Can you discuss that study and the findings?
It was really an ambitious, important, and landmark trial where the intent was terrific. It was in the United States. It took a large population of men and randomized them—where half of them got PSA screening, and half of them did not—and saw if screening for prostate cancer saves lives.
When the data were originally presented many years ago, it did not [indicate that screening] saves lives and everyone was taken aback. It has informed policy here and elsewhere really going against PSA screening. Well, it turns out—which has been known for a while but not to the extent as the recent data shows—90% of men in the control arm, meaning the men who were never supposed to get a PSA, either got a PSA before the trial or during the trial.
... to read the full story